Perioperative adjuvant therapy with infliximab in complicated anal crohn's disease

International Journal of Colorectal Disease

Volumn 23, Issue 10, 2008, Pages 965-969

  Kraemer, M ^a   Kirschmeier, A ^b   Marth, T ^b  

^a Abteilung Allgemeine und Viszeralchirurgie   (Germany)

^b Abteilung Innere Medizin mit den Schwerpunkten Gastroenterologie   (Germany)

Author keywords

Anal fistula; Anal sepsis; Chronic in flammatory bowel disease; Interdisciplinary therapy

Indexed keywords

INFLIXIMAB;

ADJUVANT THERAPY; ADULT; ANUS; ANUS FISTULA; ANUS SURGERY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROHN DISEASE; DRUG ERUPTION; DRUG USE; FEMALE; FOLLOW UP; HUMAN; MALE; OUTCOME ASSESSMENT; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; RELAPSE; REMISSION;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CROHN DISEASE; DIGESTIVE SYSTEM SURGICAL PROCEDURES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; PREOPERATIVE CARE; RECTAL FISTULA; TREATMENT OUTCOME;

EID: 51449121883     PISSN: 01791958     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00384-008-0500-6     Document Type: Article

References (54)

1. Buchmann P, Keighley MR, Allan RN, Thompson H, Alexander-Williams J (1980) Natural history of perianal Crohn's disease. Ten year follow-up: a plea for conservatism. Am J Surg 140:642-644
2. Keighley MR, Allan RN (1986) Current status and influence of operation on perianal Crohn's disease. Int J Colorectal Dis 1:104-107
3. Corman ML (1989) Colon and Rectal Surgery, 2nd edn. Lippincott, Philadelphia
4. Ackermann C, Tondelli P (1991) Chronisch entzündliche Darmerkrankungen. Möglichkeiten und Grenzen der chirurgischen Therapie. Ther Umsch 48:471-479
5. van der Hagen SJ, Baeten CG, Soeters PB, Beets-Tan RG, Russel MG, van Gemert WG (2005) Staged mucosal advancement flap for the treatment of complex anal fistulas: Pretreatment with noncutting Setons and in case of recurrent multiple abscesses a diverting stoma. Colorectal Dis. 7:513-518
6. Penninckx F, D'Hoore A, Filez L (2001) Advancement flap plasty for the closure of anal and recto-vaginal fistulas in Crohn's disease. Acta Gastroenterol Belg 64:223
7. Sangwan YP, Schoetz DJ Jr, Murray JJ, Roberts PL, Coller JA (1996) Perianal Crohn's disease. Results of local surgical treatment. Dis Colon Rectum 39:529-535
8. Fleshner PR, Schoetz DJ Jr, Roberts PL, Murray JJ, Coller JA, Veidenheimer MC (1995) Anal fissure in Crohn's disease: A plea for aggressive management. Dis Colon Rectum 38:1137-1143
9. Williamson PR, Hellinger MD, Larach SW, Ferrara A (1995) Twenty-year review of the surgical management of perianal Crohn's disease. Dis Colon Rectum 38:389-392
10. Strong SA, Fazio VW (1999) Surgical treatment of inflammatory bowel disease. Curr Opin Gastroenterol 15:326-330
11. Kroesen A-J, Buhr H-J (1999) Anorektale Fisteln bei Morbus Crohn. Zentralbl-Chir 124(Suppl 23):4-8
12. Marchesa P, Hull T-L, Fazio V-W (1998) Advancement sleeve flaps for treatment of severe perianal Crohn's disease. Br J Surg 85:1695-1698
13. O'Leary D-P, Milroy C-E, Durdey P (1998) Definitive repair of anovaginal fistula in Crohn's disease. Ann R Coll Surg Engl 80:250-252
14. Halme L, Sainio AP (1995) Factors related to frequency, type, and outcome of anal fistulas in Crohn's disease. Dis Colon Rectum 38:55-59
15. Michelassi F, Melis M, Rubin M, Hurst R-D (2000) Surgical treatment of anorectal complications in Crohn's disease. Surgery 128:597-603
16. Hull T-L, Fazio V-W (1997) Surgical approaches to low anovaginal fistula in Crohn's disease. Am J Surg 173:95-98
17. Halme L, Sainio AP (1995) Factors related to frequency, type, and outcome of anal fistulas in Crohn's disease. Dis Colon Rectum 38:55-59
18. Poupardin C, Lémann M, Gendre JP, Sabaté JM, Marteau P, Chaussade S, Delchier JC, Bouhnik Y, Chaput JC, Poupon R, Soulé JC, Benhamou Y, Grangé JD, Coffin B (2006) Efficacy of infliximab in Crohn's disease. Results of a retrospective multicenter study with a 15-month follow-up. Gastroenterol Clin Biol 30:247-252
19. Rudolph SJ, Weinberg DI, McCabe RP (2008) Long-Term Durability of Crohn's Disease Treatment with Infliximab. Dig Dis Sci 53(4):1033-1041
20. Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata ML, Cicala M (2007) Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up. World J Gastroenterol 13:5238-5244
21. Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ (1999) Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 116:22-28
22. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ (1999) Successful management of Crohn's disease of the ileoanal pouch with infliximab. Gastroenterology 117:429-432
23. Barabino A, Castellano E, Gandullia P, Biscaldi E (2000) A girl with severe fistulizing Crohn's disease. Dig Liver Dis 32:792-794
24. Farrell RJ, Shah SA, Lodhavia PJ, Alsahli M, Falchuk KR, Michetti P, Peppercorn MA (2000) Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am J Gastroenterol 95:3490-3497
25. Cohen RD (2001) Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. Inflamm Bowel Dis 7(Suppl 1):S17-22
26. Fefferman DS, Shah SA, Alsahlil M, Gelrud A, Falchulk KR, Farrell RJ (2001) Successful treatment of refractory esophageal Crohn's disease with infliximab. Dig Dis Sci 46:1733-1735
27. Miller AM, Elliott PR, Fink R, Connell W (2001) Rapid response of severe refractory metastatic Crohn's disease to infliximab. J Gastroenterol Hepatol 16:940-942
28. Hanauer SB (1999) Review article: Safety of infliximab in clinical trials. Aliment Pharmacol Ther 13(Suppl 4):16-22
29. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van-Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van-Deventer SJ (1999) Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. Gastroenterology 117:761-769
30. Regueiro M, Mardini H (2003) Treatment of perianal fistulising Crohn's disease with Infliximab alone or as an adjunct to exam under anesthesia with seton placement. Inflamm Bowel Dis 9:98-103
31. Topstad DR, Pannacione R, Heine JA, Johnson DR, MacLean AR, Buie WD (2003) Combined seton placement, Infliximab infusion, and maintenance immunosuppressive improve healing rate in fistulising anorectal Crohn's disease: A single center experience. Dis Colon Rectum 46:577-583
32. Talbot C, Sagar PM, Johnston MJ, Finan PJ, Burke D (2005) Infliximab in the surgical management of complex fistulating anal Crohn's disease. Colorectal Dis 7:164-168
33. Hyder SA, Travis SP, Jewell DP, McC Mortensen NJ, George BD (2006) Fistulating anal Crohn's disease: Results of combined surgical and Infliximab treatment. Dis Colon Rectum 49:1837-1841
34. Sorrentino D, Terrosu G, Avellini C, Beltrami CA, Bresadola V, Toso F (2006) Prevention of postoperative recurrence of Crohn's disease by Infliximab. Eur J Gastroenterol Hepatol 18:457-459
35. van der Hagen SJ, Baeten CG, Soeters PB, Russel MG, Beets-Tan RG, van Gemert WG (2005) Anti-TNF-alpha (infliximab) used as induction treatment in case of active proctitis in a multistep strategy followed by definite surgery of complex anal fistula in Crohn's disease: A preliminary report. Dis Colon Rectum 48:758-767
36. Willis S, Rau M, Schumpelick V (2000) Chirurgische Therapie hoher anorectaler und rectovaginaler Fisteln mittels transanaler endorectaler Verschiebelappenplastik. Chirurg 71:836-840
37. Hyman N (1999) Endoanal advancement flap repair for complex anal fistula. Am J Surg 178:337-340
38. Del Pino A, Nelson RL, Pearl RK, Abcarian H (1996) Island flap anoplasty for treatment of transsphincteric fistula-in-ano. Dis Colon Rectum 39:224-226
39. Gemsenjager E (1996) Erfahrungen mit einem neuen Therapiekonzept bei Analfistel: Naht des analen Sphinkters. Schweiz Med Wochenschr 126:2021-2025
40. Kohler A, Athanasiadis S (1996) Die anodermale Verschiebelappenplastik als alternative Behandlungsmethode zu den endorectalen Verschlusstechniken bei der Therapie hoher Analfisteln. Eine prospektive Studie bei 31 Patienten. Chirurg 67:1244-1250
41. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van-Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van-Deventer SJ (1999) Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340:1398-1405
42. Rutgeerts P (2000) Management of perianal Crohn's disease. Can J Gastroenterol 14(Suppl C):7C-12C
43. Serrano MS, Schmidt-Sommerfeld E, Kilbaugh TJ, Brown RF, Udall JN Jr, Mannick EE (2001) Use of infliximab in pediatric patients with inflammatory bowel disease. Ann Pharmacother 35:823-828
44. van-Bodegraven AA, Sloots CEJ, Felt-Bersma RJF, Meuwissen SGM (2002) Endosonographic evidence of persistence of Crohn's disease-associated fistulas after infliximab treatment, irrespective of clinical response. Dis Colon Rectum 45:39-45
45. Bell SJ, Halligan S, Windsor AC, Williams AB, Wiesel P, Kamm MA (2003) Response of fistulating Crohn's disease to infliximab treatment assessed by magnetic resonance imaging. Aliment Pharmacol Ther 17:387-393
46. Van Assche G, Vanbeckevoort D, Bielen D, Coremans G, Aerden I, Noman M, D'Hoore A, Penninckx F, Marchal G, Cornillie F, Rutgeerts P (2003) Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease. Am J Gastroenterol 98:332-339
47. Ardizzone S, Maconi G, Colombo E, Manzionna G, Bollani S, Bianchi Porro G (2004) Perianal fistulae following infliximab treatment: Clinical and endosonographic outcome. Inflamm Bowel Dis 10:91-96
48. Rasul I, Wilson SR, MacRae H, Irwin S, Greenberg GR (2004) Clinical and radiological responses after infliximab treatment for perianal fistulizing Crohn's disease. Am J Gastroenterol 99:82-88
49. Blonski W, Lichtenstein GR (2007) Safety of biologic therapy. Inflamm Bowel Dis 13:769-796
50. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, Pritchard ML, Sandborn WJ (2006) Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 4:621-630
51. Rutgeerts P (2002) A critical assessment of new therapies in inflammatory bowel disease. J Gastroenterol Hepatol 17(Suppl):S176-S185
52. Andus T, Stange EF, Höffler D, Keller-Stanislawski B (2003) Verdachtsfälle schwerwiegender Nebenwirkungen nach Infliximab (Remicade) aus Deutschland. Med Klin 98:429-436
53. Lichtenstein GR (2000) Treatment of fistulizing Crohn's disease. Gastroenterology 119:1132-1147
54. Pehl C, Schepp W (2005) Medikamentöse Therapie anorektaler Crohn-Fisteln. Deutsches Ärzteblatt 102:433-437